1[1]Legro RS,Kunselman A,Dodson WC,et al.Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome:a prospective,controlled study in 254 affected women.J Clin Endocrinol Metab,1999,84:165-169
2[2]White MF,Yenush L.The IRS-signaling system:a network of docking proteins that mediate insulin and cytokine action.Curr Top Microbiol Immunol,1998,228:179-208
3[3]Dunaif A,Aradhana M,Corbould A,et al.Insulin resistance in polycystic ovary syndrome:progress and paradoxes.Recent Prog Horm Res,2001,56:295-308
4[4]Li M,Youngren JF,Dunaif A,et al.Decreased insulin receptor(IR) autophorylation in fibroblasts from patients with PCOS:effects of serine kinase inhibitors and IR activators.J Clin Endocrinol Metab,2002,87:4088-4093
5[5]Dunaif A.Insulin resistance and polycystic ovary syndrome:mechanism and implications for pathogenesis.Endocrine review,1997,18:774-800
6[6]Leroith D,Werner H,Beitner-Johnson D,et al.Molecular and cellular aspects of the insulin-like growth factor Ⅰreceptor.Endocrine review,1995,16:143-163
7[7]Rincon J,Holmang A,Wahlstrom EO,et al.Mechanisms behind insulin resistance in rat skeletal muscle after oophorectomy and additional testosterone treatment.Diabetes,1996,45:615-621
8[8]Mogetti P,Tosi F,Castello R,et al.The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment:evidence that androgens impair insulin action in women.J Clin Endocrinol Metab,1996,81:952-960
9[9]Roy Homburg.Should patients with polycystic ovary syndrome be treated with metformin?Hum Repro,2002,17:853-856
10[10]Moghetti P,Castello R,Negri C,et al.Metformin effect on clinical features,endocrine and metabolic profiles and insulin sensitivity in polycystic ovary syndrome:a randomized,double blind,placebo-controlled 6-month trail,followed by open,long-term clinical evaluation.J.Clin.Endocrinol.Metab,2000,85:139-146
